The Global Hypertrophic Cardiomyopathies (HCM) Therapeutics Market Continues To Grow Owing To Governmental Initiatives towards Research and Development and the Prevalence of Obesity
Hypertrophic cardiomyopathies (HCM) therapeutics are treatments for Hypertrophic cardiomyopathies, which is the commonest acquired carcinomatous disease. People are genetically born with it, however, hypertrophy does not appear to begin developing till adolescence, after growth spurts, an age where many people have acquired this disease. Symptoms may not be apparent until the disease is far advanced, and often people do not even realize they have it until it is too late. Diagnosis is difficult, as the symptoms are so subtle, and unless a heart tracing test is done, usually the doctor can't accurately say whether the patient has the disease or not. Most people with Hypertrophic Cardiomyopathy have at least a few of the following symptoms: breathlessness when lying down; shortness of breath upon standing; palpitations; irregular heartbeat; nausea; vomiting; diarrhea; abdominal bloating; headaches; back pain; jaw pain; fatigue; pale skin; and swelling of legs. While some patients ...